Previous 10 | Next 10 |
CHARLESTON, S.C., July 30, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the abstract on study resul...
Nasdaq notifies Aeterna Zentaris (NASDAQ: AEZS ) -2% that it no longer meets its listing requirement of a minimum of $1/share. More news on: Aeterna Zentaris Inc., Healthcare stocks news, Read more ...
CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announc...
CHARLESTON, S.C., July 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of its previously an...
3 Penny Stocks To Watch Before The Weekend There are never dull moments with penny stocks . Most of the time, these stocks under $5 have a proper mix of speculative momentum and fundamental catalysts that can see huge moves. Sometimes these moves are long-lasting while other times they’...
Aeterna Zentaris (NASDAQ: AEZS ) has priced its offering of ~26.7M units at $0.45/unit, for gross proceeds of $12M. Each unit contains one common share and one common warrant to purchase one common share. More news on: Aeterna Zentaris Inc., Healthcare stocks news, , Read more ...
CHARLESTON, S.C., July 01, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the pricing of a public offering...
Aeterna Zentaris (NASDAQ: AEZS ) is up 10% premarket after entering into an exclusive distribution and related quality agreement with Megapharm Ltd., for the commercialization of Aeterna's macimorelin, an orally available ghrelin agonist used for the assessment of gro...
CHARLESTON, S.C, June 25, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an ...
Aeterna Zentaris (NASDAQ: AEZS ) has regained compliance with the Nasdaq minimum bid price requirement for continued listing. More news on: Aeterna Zentaris Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
2024-07-17 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...